UNSPSC 51152006: Cisatracurium

This classification denotes a nicotinic antagonist with the molecular formula C53H72N2O12, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier QX62KLI41N, chemically known as isoquinolinium, 2,2-(1,5-pentanediylbis(oxy(3-oxo-3,1-propanediyl)))bis(1-((3,4-dimethoxyphenyl)methyl)-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-, dibenzenesulfonate, (1r-(1alpha,2alpha(1r(sup *),2r(sup *))))- but generally known as cisatracurium, which bears US NIH Compound Identifier 62886.

UNSPSC 51152006 Cisatracurium is a Commodity code that nominally covers a specific paralytic agent used in anesthesia and critical care. The recent state and local opportunities tagged under this code, however, show a significant mismatch: Seminole County, Florida solicited naloxone and drug deactivation systems; Texas HHS issued a Request for Information on direct-to-manufacturer prescription programs; and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) sought generic multi-source pharmaceuticals and over-the-counter products broadly. None of these solicitations involve cisatracurium specifically. The code shows little relevant recent activity targeting the actual pharmaceutical product it nominally describes. The issuing bodies do span state health agencies, county health departments, and cooperative purchasing vehicles, but the mismatch between code assignment and actual procurement scope suggests the code is not in active use for its intended commodity among state and local buyers.

The geographic spread visible in the records includes Florida, Texas, and Minnesota, but activity appears sparse and scattered rather than concentrated. The Seminole County IFB (due July 26, 2023) sought naloxone in an emergency-response context; the Texas HHS RFI (due April 3, 2026) explored pharmacy benefit model restructuring; and MMCAP's RFP (due March 26, 2026) targeted commodity pharmaceuticals and OTC items across multiple states. Without recent, direct solicitations for cisatracurium itself, business development professionals should treat this code as inactive for state and local procurement purposes and verify whether the actual pharmaceutical or product of interest carries a different UNSPSC assignment.